{"schema_version":"1.0","type":"article","title":"神藥 猛健樂 Tirzepatide 進軍自體免疫，只差臨門一腳？","url":"https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism.md","lang":"zh-Hant","date":"2026-06-26","publish_at":"2026-06-26T10:30:00+08:00","updated_at":"2026-06-26","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","GLP-1","臨床數據","生技投資","製藥巨頭"],"summary":"它不像急性感染，用藥幾天或幾週就結束。類風濕性關節炎、乾癬、乾癬性關節炎、發炎性腸道疾病、氣喘、異位性皮膚炎，這些疾病往往跟著患者一輩子。","key_points":[],"facts":[],"sections":["Tirzepatide 進軍自體免疫，只差臨門一腳：GLP-1 的下一個戰場，可能不是減重，而是免疫發炎","01｜Zepbound + Taltz：Lilly 把減重藥放進免疫疾病治療框架","02｜為什麼是乾癬與乾癬性關節炎？因為肥胖與免疫發炎本來就綁在一起","03｜Tirzepatide 進軍自免，真正賣點不是「減肥」，而是「免疫代謝」","04｜Lilly 沒有只押乾癬，下一站是腸道發炎疾病","05｜自免市場從來不缺錢，缺的是下一個能接棒的邏輯","06｜Tirzepatide 能為 Lilly 帶來什麼？不是多賣一點藥，而是重新定義 Zepbound 的邊界","07｜但還不能說 GLP-1 已經正式成為自免藥","08｜台灣看免疫代謝與皮膚免疫藥物的外溢","結語｜Zepbound 進軍自免，不是跨界噱頭，而是疾病分類正在重寫"],"references":[{"title":"[1] Eli Lilly and Company","source":"Zepbound (tirzepatide) U.S. prescribing information:","date":"","url":"https://uspl.lilly.com/zepbound/zepbound.html#pi"},{"title":"[2] Eli Lilly and Company","source":"Taltz (ixekizumab) U.S. prescribing information:","date":"","url":"https://uspl.lilly.com/taltz/taltz.html#pi"},{"title":"[3] Eli Lilly and Company","source":"COMMIT-CD clinical trial: mirikizumab and tirzepatide in Crohn's disease with obesity or overweight:","date":"","url":"https://trials.lilly.com/en-US/trial/600156"},{"title":"[4] Eli Lilly and Company","source":"Omvoh (mirikizumab) U.S. prescribing information:","date":"","url":"https://uspl.lilly.com/omvoh/omvoh.html#pi"},{"title":"[5] AbbVie","source":"Rinvoq (upadacitinib) U.S. prescribing information:","date":"","url":"https://www.rxabbvie.com/pdf/rinvoq_pi.pdf"}],"images":[{"alt":"Facebook 原圖：神藥 猛健樂 Tirzepatide 進軍自體免疫，只差臨門一腳？（圖 1）","url":"https://drugnews.com.tw/assets/articles/tirzepatide-autoimmune-immunometabolism/facebook-01.png"},{"alt":"Facebook 原圖：神藥 猛健樂 Tirzepatide 進軍自體免疫，只差臨門一腳？（圖 2）","url":"https://drugnews.com.tw/assets/articles/tirzepatide-autoimmune-immunometabolism/facebook-02.png"},{"alt":"Facebook 原圖：神藥 猛健樂 Tirzepatide 進軍自體免疫，只差臨門一腳？（圖 3）","url":"https://drugnews.com.tw/assets/articles/tirzepatide-autoimmune-immunometabolism/facebook-03.png"},{"alt":"Facebook 原圖：神藥 猛健樂 Tirzepatide 進軍自體免疫，只差臨門一腳？（圖 4）","url":"https://drugnews.com.tw/assets/articles/tirzepatide-autoimmune-immunometabolism/facebook-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/tirzepatide-autoimmune-immunometabolism/cover-generated.svg","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-26）。神藥 猛健樂 Tirzepatide 進軍自體免疫，只差臨門一腳？。https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-06-26-tirzepatide-autoimmune-immunometabolism-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}